Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 15, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 18, 2025
CEOOption exercise
Context
Classification
option exercise
Code C — exercise or conversion of a derivative security
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001256153-25-000004
Filed / recorded
Dec 18, 2025, 9:15 PM UTC
Added to OQRO
Oct 7, 2026, 5:52 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Ovid Therapeutics Inc.
Issuer CIK
1636651
Ticker
OVID
Reporting person
Jeremy M Levin
Relationship
Director, Officer
Officer title
CEO
Security
Series B Convertible Preferred Stock
Table
Derivative (Table II)
Transaction date
Dec 15, 2025
Transaction code
C
Shares / units
71
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.